Early/delayed cardiotoxicity; active or dormant CV disease, prior or concomitant radiotherapy to mediastinal/pericardial area, previous therapy w/ other anthracyclines or anthracenediones & concomitant use of drugs w/ ability to suppress cardiac contractility or cardiotoxic drugs eg, trastuzumab. Severe myelosuppression. Secondary leukemia, GI complications, tumor lysis syndrome, thrombophlebitis & thromboembolic phenomena. Inj site effects, extravasation. Assess cardiac function, hematologic profile before & during treatment. Evaluate blood uric acid, K, Ca phosphate & creatinine levels after initial treatment. Avoid use w/ live vaccine. Hepatic &/or renal impairment. Women of childbearing potential. May impair fertility in men. Pregnancy. Not to be used during lactation.